Alliance Statement On Ag/FDA Spending Bill Adopted By The House Appropriations Committee
For more information, contact Steven Grossman
sgrossman@strengthenfda.org or 301-257-9660
In response to media inquiries, the Alliance for a Stronger FDA released the following statement:
July 11, 2024 | Silver Spring, MD – The Ag/FDA spending bill adopted by the House Appropriations Committee last night was disappointing. It provides the FDA with about $20 million less in taxpayer money in FY 25 than is available to the agency in the current fiscal year. As a practical matter, the decrease is actually much larger because the diminished level of FY 25 funding will nonetheless need to fund new initiatives, program growth, mandatory salary increases, and building and facilities repairs. The net loss for the Agency is at least $150 million compared to the FY 24 final appropriations.
This morning’s Senate Appropriations Committee-adopted Ag/FDA funding bill is an improvement, but it still leaves the agency with significantly less money than it will need in FY 25. It includes a small increase of $22 million in taxpayer spending. However, the Agency will still need well above that amount to pay for new initiatives, program growth, and mandatory salary increases. The net loss for the agency is at least $100 million compared to the FY 24 final appropriations.
FDA continues to enjoy bipartisan support in Congress, reflected by Members’ statements in support of the agency’s importance. Additionally, there is uncertain potential that a higher spending limit in the Senate may ultimately ease constraints on spending.
We will continue to press Congress to recognize and fund FDA’s vital work. We also welcome any development where increased total federal spending could translate into tangible support for FDA’s expanding mission and growing responsibilities.
--
The Alliance for a Stronger FDA is a stakeholder organization with 150+ members devoted to advocating for increased appropriations for the FDA and educating policymakers and the public about the FDA's mission and responsibilities. The Alliance’s unique coalition of patients, consumers, and industry mirrors FDA’s unique role in public health, safety, and commerce.